Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent E Pryor

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Pharmaceutical Design|May 29, 2012
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic strokePatricia D Williams, Berislav V Zlokovic, John H Griffin, et al.
Stroke|June 23, 2020
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of TenecteplasePurba Mukherjee, Patrick Lyden, José A Fernández, et al.
Frontiers in Neurology|April 1, 2021
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic TransformationPatrick D Lyden, Kent E Pryor, Jennifer Minigh, et al.
Annals of Neurology|November 20, 2018
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic StrokePatrick Lyden, Kent E Pryor, Christopher S Coffey, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Pharmaceutical Design|May 29, 2012
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic strokePatricia D Williams, Berislav V Zlokovic, John H Griffin, et al.
Stroke|June 23, 2020
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of TenecteplasePurba Mukherjee, Patrick Lyden, José A Fernández, et al.
Frontiers in Neurology|April 1, 2021
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic TransformationPatrick D Lyden, Kent E Pryor, Jennifer Minigh, et al.
Annals of Neurology|November 20, 2018
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic StrokePatrick Lyden, Kent E Pryor, Christopher S Coffey, et al.
Pageof 1